Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ARVO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinical study abstracts originally presented this past April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigative Ophthalmology & Visual Science, by a team of scientists led by Dr. Christopher Leung from the Departme